Journal of IMAB - Annual Proceeding (Scientific Papers)
, Gospodin Iliev
ISSN: 1312 773X
Year: 2007, vol. 13, issue 1
Subject Collection: Medicine
Online date: November 14, 2007
J of IMAB 2007; 13(1):68-70
GENERALIZED MORPHEA: A case report
Valentina Dimitrova, Ivelina Yordanova, Dimitar K. Gospodinov
Department of Dermatology and Venereology, Medical University - Pleven, Bulgaria
Generalized morphea is a subtype of localized scleroderma, which lacks systemic manifestations and displays widespread, multiple, well-circumscribed, indurated plaques.
We represent a 46-year-old woman with generalized morphea. More than 3 years ago she developed multiple, nonpruritic plaques symmetrically on the trunk and extremities.
The patient’s clinical history, laboratory analysis and histopathologic examination were consistent with generalized morphea, a rare subtype of localized scleroderma.
Key words: localized scleroderma, morphea, generalized morphea.
- Download FULL TEXT (PDF - 640 KB)
Please cite this article as:
Dimitrova V, Yordanova I, Gospodinov DK. Generalized morphea: a case report. J of IMAB 2007; 13(1):68-70. doi: 10.5272/jimab.2007131.64
1. Jemal A, Tiwari RC, Murray T et all, Cancer Statistics, 2004. CA Cancer J Clin 2004;54:8–29.
2. Glimelius B, Hofman K, Graf W at all, Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Cancer 1994; 73: 556–562.
3. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer 1997; 80: 1179–1187.
4. Meta-analysis Group in Cancer. Efficacy of IV continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–308.
5. Pommier Y, Tanizava A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. In: Liu LF, ed. Advanced in pharmacology. New York: Academic Press 1994; 29B; 73-92
6. Saltz LB, Cox JV, Blanke C et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412
7. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first- line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355: 1371
8. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47; 207-214
9. Brimdage MD, Pater JL, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85; 38-48
10. Kaplan EL, Meyer P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959; 53; 457- 481
11. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22; 229-237
12. Goldberg RM, Sargent DJ, Morton RF et all: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxalplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22; 23-30
back to Online Journal